Browsing Tag
Kodiak Sciences
6 posts
Nasdaq: KOD — Is Kodiak Sciences’ KSI-101 finally turning Wall Street bullish on ocular inflammation?
Explore how Kodiak Sciences’ KSI‑101 is reshaping the retinal‑disease treatment landscape and why JPMorgan just upgraded the stock—read more now!
Kodiak Sciences advances Phase 3 study of tarcocimab tedromer in diabetic retinopathy
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing transformative therapeutics for retinal diseases, announced that…
Kodiak Sciences’ KSI-301 fails to meet primary endpoint in wet AMD trial
Kodiak Sciences said that its antibody biopolymer conjugate KSI-301 failed to meet the primary endpoint in a phase…
KSI-301 phase 1b trial : Kodiak Sciences reports new safety, efficacy, and durability data
KSI-301 phase 1b trial : Kodiak Sciences said that its ongoing phase 1b clinical trial of its intravitreal…
DAZZLE clinical trial : Kodiak Sciences doses first patients with KSI-301 in phase 3 wet AMD trial
Kodiak Sciences said that it has treated the first patients in the phase 2 DAZZLE clinical trial of…
Kodiak Sciences completes enrollment for KSI-301 safety study in retinal disease
Kodiak Sciences, a California-based biotechnology company, has recently completed patient enrollment for a phase 1 safety and tolerability…